Helus Pharma Appoints CEO Ahead of Expected Q4 2026 Data

- Helus Pharma has appointed a new CEO to lead the company as it advances its lead candidate, HLP003, toward potential commercialization.
- The company announced that enrollment is now complete for the APPROACH clinical trial, with topline data expected to be released in Q4 2026.
- Enrollment remains ongoing for the EMBRACE trial, as the company works to confirm the effectiveness and safety of the treatment in large patient groups.
- These Phase 3 results are critical for investors, as they will determine the drug's regulatory approval path, market valuation, and potential to treat hard-to-treat conditions.
Sources & Citations
1 sourceMore Stories
Medical Bulletin 03/August/2026
• A new medical review suggests that reducing protein consumption may slow biological aging and extend lifespan by improving metabolism and lowering inflammation. • Research indicates that protein restriction preserves healthy cell function and reduces cellular damage, with similar benefits previously observed in flies and rodents.
Read original · medicaldialogues.inMonday, August 3, 2026 - KFF Health News
• The Department of Veterans Affairs is launching a randomized clinical trial to determine if GLP-1 drugs can reduce alcohol abuse among U.S. military veterans. • The study will specifically measure whether semaglutide, the active ingredient in Novo Nordisk’s Ozempic and Wegovy, can decrease drinking and improve overall quality of life.
Read original · kffhealthnews.orgMental Health News -- ScienceDaily
• New research indicates that individuals using cannabis for self-medication face increased risks of paranoia and typically consume higher levels of THC. • The study highlights that childhood trauma further amplifies these psychological risks, creating a more dangerous interaction for vulnerable users.
Read original · sciencedaily.comA Timeline of COVID-19 Developments in 2020
• COVID-19 dominated the global landscape throughout 2020, evolving from an emerging health crisis to a pandemic that concluded the year with the arrival of vaccines. • Overwhelmed hospitals struggled with severe resource shortages, specifically lacking enough personal protective equipment (PPE) to maintain standard operations.
Read original · ajmc.comHHS releases government-wide policy to prohibit gain-of-function research - The Cancer Letter
• The Trump Administration and the Department of Health and Human Services (HHS) have released the "United States Government Policy for Stopping High-Risk Life Sciences Research." • This new framework explicitly prohibits federally supported gain-of-function research that is deemed dangerous to public health.
Read original · cancerletter.com
The Cancer LetterReuters Health News Summary
• An FDA advisory panel voted on Thursday to support trial results for Replimune's drug, RP1, which targets a specific type of skin cancer. • The FDA had previously declined to approve RP1 twice, most recently in April, due to a lack of a control group and insufficient evidence of effectiveness.
Read original · devdiscourse.com
DevdiscourseCyclosporiasis Outbreak 2026: 145 Cases Across 17 States, CDC Alert for Health Care Workers
• A Cyclosporiasis outbreak has been reported across 17 states, with 145 confirmed cases of the gastrointestinal disease caused by the Cyclospora parasite. • The CDC has issued an alert to health care workers to ensure rapid diagnosis and proper response, as the infection spreads via contaminated food or water.
Read original · infectioncontroltoday.comOver 400 state vaccine bills, 9 new laws, 2 fed charters, and 1 step closer to a CDC director: The State of US Vaccine Policy
• The U.S. is seeing a surge in vaccine policy activity, with over 400 state vaccine bills introduced and nine new laws enacted. • New federal charters have been established through July 2028, focusing on healthy lifestyle initiatives, dietary supplements, and FDA-approved off-label drug use.
Read original · cidrap.umn.eduMedical Bulletin 31/July/2026
• A new AI tool called MEDWACS has been developed to identify undiagnosed individuals with type 2 diabetes using over 30 years of U.S. health data. • The findings, published in the Journal of Clinical Epidemiology, highlight the tool's ability to detect the disease before patients seek medical testing.
Read original · medicaldialogues.inQz
• An FDA advisory panel voted 10-3 on Thursday in favor of Replimune Group's experimental melanoma treatment, RP1. • The committee concluded that efficacy results from the company's IGNYTE clinical trial were both evaluable and clinically meaningful.
Read original · qz.comFederal government could improve infectious disease monitoring, says federal government
• The nominee for the director of the Centers for Disease Control and Prevention (CDC) has advanced to a full Senate vote. • The federal government indicated that Medicaid work requirements will not be delayed, maintaining current policy timelines.
Read original · statnews.com
Statnews